Venobotic
Automated CVAD Blood Sampling and Flushing for Safer Central-line Care
Company Overview
Snapshot
Founded in March 2025 by Michal Singer, Venobotic operates with 1–10 employees. The company secured its first disclosed funding round from eHealth Ventures in May 2026, marking a significant early-stage investment in its medical device platform.
Business overview
Venobotic develops LineGuard, an automated medical device platform designed for blood sampling, flushing, and disinfection through Central Venous Access Devices (CVADs). This technology aims to replace manual CVAD handling with a standardized automated workflow, reducing contamination risks, improving protocol consistency, and saving nursing time. The company targets hospitals, oncology units, ICUs, post-operative wards, community clinics, home infusion, and palliative-care providers within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
Company Intelligence Q&A
- What is Venobotic's core product?
- Venobotic's core product is LineGuard, an automated medical device platform for blood sampling, flushing, and disinfection through Central Venous Access Devices.
- When was Venobotic founded?
- Venobotic was founded in March 2025.
- Who is a co-founder of Venobotic?
- Michal Singer is a co-founder and Scientific Advisor at Venobotic.
- What is LineGuard designed to do?
- LineGuard is designed to replace manual CVAD handling with a standardized automated workflow, reducing contamination risks, improving protocol consistency, and saving nursing time.
- What markets does Venobotic target?
- Venobotic targets the Israeli and United States markets with its medical device solutions.